Skip to content

Study · Animal study (in vivo) · mouse · 2002

7 results

Thymulin reduces the hyperalgesia and cytokine upregulation induced by cutaneous leishmaniasis in mice.

Kanaan SA, Safieh-Garabedian B, Karam M, Khansa H, Jabbur SJ, Jurjus AR, Saade NE

Brain, behavior, and immunity1 Aug 2002Cited by 5 (Europe PMC)

PMID12096890 (opens in a new tab)DOI10.1006/brbi.2001.0631 (opens in a new tab)PepBankPUB-12096890
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cutaneous leishmaniasis, daily thymulin reduced hyperalgesia dose-dependently in the tail flick test.

    In plain wordsIn mice with cutaneous leishmaniasis, daily thymulin reduced hyperalgesia in the tail flick test as dose increased.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseTail flick hyperalgesia
    Study

    mousen: not reported in source

    cutaneous leishmaniasis in mice
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    1, 100, and 1000 ng · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Daily treatment with thymulin (1, 100, and 1000 ng/ip) produced dose-dependent decreases in CL-induced hyperalgesia as assessed by the tail flick and the hot plate tests.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cutaneous leishmaniasis, daily thymulin reduced hyperalgesia dose-dependently in the hot plate test.

    In plain wordsIn mice with cutaneous leishmaniasis, daily thymulin reduced hyperalgesia in the hot plate test as dose increased.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseHot plate hyperalgesia
    Study

    mousen: not reported in source

    cutaneous leishmaniasis in mice
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    1, 100, and 1000 ng · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Daily treatment with thymulin (1, 100, and 1000 ng/ip) produced dose-dependent decreases in CL-induced hyperalgesia as assessed by the tail flick and the hot plate tests.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cutaneous leishmaniasis, thymulin reversed sustained increases in skin IL-1beta levels.

    In plain wordsIn mice with cutaneous leishmaniasis, thymulin reversed increased skin IL-1beta levels.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseSkin IL-1beta levels in leishmaniasis
    Study

    mousen: not reported in source

    cutaneous leishmaniasis in mice
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    1 microg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Mice with CL showed sustained increase in the levels of IL-1beta and NGF which were reversed by thymulin (1 microg).
    1 context sentence
    Summary · context
    The levels of NGF and IL-1beta were determined in the skin tissues of the hind leg in different groups (n = 5 each) of mice over a period of 5 weeks.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cutaneous leishmaniasis, thymulin reversed sustained increases in skin NGF levels.

    In plain wordsIn mice with cutaneous leishmaniasis, thymulin reversed increased skin NGF levels.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseSkin NGF levels in leishmaniasis
    Study

    mousen: not reported in source

    cutaneous leishmaniasis in mice
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    1 microg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Mice with CL showed sustained increase in the levels of IL-1beta and NGF which were reversed by thymulin (1 microg).
    1 context sentence
    Summary · context
    The levels of NGF and IL-1beta were determined in the skin tissues of the hind leg in different groups (n = 5 each) of mice over a period of 5 weeks.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice, thymulin alone did not alter nociceptive thresholds.

    In plain wordsIn mice, thymulin alone did not change pain thresholds.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    No significant changeNociceptive thresholds after thymulin alone
    Study

    mousen: not reported in source

    mice receiving thymulin alone
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Injection of thymulin only did not alter the nociceptive thresholds or the levels of IL-1beta and NGF.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice, thymulin alone did not alter IL-1beta levels.

    In plain wordsIn mice, thymulin alone did not change IL-1beta levels.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    No significant changeIL-1beta levels after thymulin alone
    Study

    mousen: not reported in source

    mice receiving thymulin alone
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Injection of thymulin only did not alter the nociceptive thresholds or the levels of IL-1beta and NGF.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In mice, thymulin alone did not alter NGF levels.

    In plain wordsIn mice, thymulin alone did not change NGF levels.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    No significant changeNGF levels after thymulin alone
    Study

    mousen: not reported in source

    mice receiving thymulin alone
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Injection of thymulin only did not alter the nociceptive thresholds or the levels of IL-1beta and NGF.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:55 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.